3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Amyloid Network Topology Characterizes the Progression of Alzheimer’s Disease During the Predementia Stages

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          There is increasing evidence showing that the accumulation of the amyloid-β (Aβ) peptide into extracellular plaques is a central event in Alzheimer's disease (AD). These abnormalities can be detected as lowered levels of Aβ 42 in the cerebrospinal fluid (CSF) and are followed by increased amyloid burden on positron emission tomography (PET) several years before the onset of dementia. The aim of this study was to assess amyloid network topology in nondemented individuals with early stage Aβ accumulation, defined as abnormal CSF Aβ 42 levels and normal Florbetapir PET (CSF+/PET−), and more advanced Aβ accumulation, defined as both abnormal CSF Aβ 42 and Florbetapir PET (CSF+/PET+). The amyloid networks were built using correlations in the mean 18F-florbetapir PET values between 72 brain regions and analyzed using graph theory analyses. Our findings showed an association between early amyloid stages and increased covariance as well as shorter paths between several brain areas that overlapped with the default-mode network (DMN). Moreover, we found that individuals with more advanced amyloid accumulation showed more widespread changes in brain regions both within and outside the DMN. These findings suggest that amyloid network topology could potentially be used to assess disease progression in the predementia stages of AD.

          Related collections

          Most cited references30

          • Record: found
          • Abstract: not found
          • Article: not found

          Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Efficient Behavior of Small-World Networks

            We introduce the concept of efficiency of a network as a measure of how efficiently it exchanges information. By using this simple measure, small-world networks are seen as systems that are both globally and locally efficient. This gives a clear physical meaning to the concept of "small world," and also a precise quantitative analysis of both weighted and unweighted networks. We study neural networks and man-made communication and transportation systems and we show that the underlying general principle of their construction is in fact a small-world principle of high efficiency.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Efficient Behavior of Small-World Networks

              We introduce the concept of efficiency of a network, measuring how efficiently it exchanges information. By using this simple measure small-world networks are seen as systems that are both globally and locally efficient. This allows to give a clear physical meaning to the concept of small-world, and also to perform a precise quantitative a nalysis of both weighted and unweighted networks. We study neural networks and man-made communication and transportation systems and we show that the underlying general principle of their construction is in fact a small-world principle of high efficiency.
                Bookmark

                Author and article information

                Journal
                Cereb Cortex
                Cereb. Cortex
                cercor
                Cerebral Cortex (New York, NY)
                Oxford University Press
                1047-3211
                1460-2199
                January 2018
                09 November 2017
                09 November 2017
                : 28
                : 1
                : 340-349
                Affiliations
                [1 ] Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Stockholm, Sweden
                [2 ] Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University , Lund, Sweden
                [3 ] Memory Clinic, Skåne University Hospital , MalmöSweden
                [4 ] Department of Neurology, Skåne University Hospital , Sweden
                [5 ] Department of Physics, Göteborg University , Göteborg, Sweden
                [6 ] Department of Clinical Sciences Lund, Diagnostic Radiology, Lund University , Lund, Sweden
                [7 ] Imaging and Function, Skåne University Health Care , Lund, Sweden
                Author notes
                Address correspondence to Joana B. Pereira, Department of NVS, Division of Clinical Geriatrics, Novum fifth floor, 141 57 Huddinge, Sweden. Email: joana.pereira@ 123456ki.se
                [†]

                Eric Westman and Oskar Hansson contributed as senior authors.

                [‡]

                Data used in preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf

                Article
                bhx294
                10.1093/cercor/bhx294
                6454565
                29136123
                c2fb6baf-440f-42c7-aca4-330ff8d67a1a
                © The Author 2017. Published by Oxford University Press.

                This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@ 123456oup.com

                History
                : 09 July 2017
                : 09 October 2017
                Page count
                Pages: 10
                Funding
                Funded by: National Institutes of Health 10.13039/100000002
                Award ID: U01 AG024904
                Award ID: W81XWH-12–2-0012
                Funded by: National Institute on Aging 10.13039/100000049
                Funded by: National Institute of Biomedical Imaging and Bioengineering 10.13039/100000070
                Funded by: Canadian Institutes of Health Research 10.13039/501100000024
                Funded by: Alzheimer’s Disease Neuroimaging Initiative
                Funded by: Alzheimer’s Association
                Funded by: Alzheimer’s Drug Discovery Foundation
                Funded by: BioClinica, Inc. 10.13039/100007742
                Funded by: Biogen Idec Inc.
                Funded by: Bristol-Myers Squibb Company 10.13039/100002491
                Funded by: Eisai Inc.
                Funded by: Elan Pharmaceuticals, Inc.
                Funded by: Eli Lilly and Company 10.13039/100004312
                Funded by: F. Hoffmann-La Roche Ltd 10.13039/100007013
                Funded by: Genentech, Inc. 10.13039/100004328
                Funded by: GE Healthcare 10.13039/100006775
                Funded by: Innogenetics, N.V.
                Funded by: IXICO Ltd.
                Funded by: Janssen Alzheimer Immunotherapy Research & Development, LLC.
                Funded by: Johnson & Johnson Pharmaceutical Research & Development LLC.
                Funded by: Medpace, Inc.
                Funded by: Merck & Co., Inc.
                Funded by: Meso Scale Diagnostics, LLC.
                Funded by: NeuroRx Research
                Funded by: Novartis Pharmaceuticals Corporation 10.13039/100008272
                Funded by: Pfizer Inc. 10.13039/100004319
                Funded by: Piramal Imaging
                Funded by: Servier
                Funded by: Synarc Inc.
                Funded by: Takeda Pharmaceutical Company 10.13039/100008373
                Funded by: Northern California Institute for Research and Education 10.13039/100009804
                Funded by: Alzheimer’s Disease Cooperative Study at the University of California, San Diego
                Funded by: Laboratory for Neuro Imaging at the University of California, Los Angeles
                Funded by: European Research Council 10.13039/501100000781
                Funded by: Swedish Research Council
                Funded by: Swedish Alzheimer Foundation
                Funded by: Swedish Brain Foundation 10.13039/501100003792
                Funded by: Marianne and Marcus Wallenberg Foundation
                Funded by: Swedish Foundation for Strategic Research (SSF)
                Funded by: Karolinska Institutet (StratNeuro)
                Funded by: Hjärnfonden
                Funded by: Birgitta och Sten Westerberg
                Funded by: Åke Wiberg Foundation
                Funded by: Swedish Federal Government
                Categories
                Original Articles

                Neurology
                amyloid,brain networks,cerebrospinal fluid,florbetapir pet,graph theory
                Neurology
                amyloid, brain networks, cerebrospinal fluid, florbetapir pet, graph theory

                Comments

                Comment on this article